The Medical Technology Research Group (MTRG) is a research unit within the London School of Economics and Political Science (LSE) concentrating on interdisciplinary and comparative policy research on medical technologies. The group aims to produce high quality research and to provide education, training, policy support and advice to key stakeholders, including governments and international organisations. Central to the activities of the group and its members is a focus on policy analysis and policy evaluation.
The primary research areas within the group are as follows:
First, the economics of medical technologies, in particular, medicines and medical devices, where the focus is on researching the financing mechanisms for and access to medical technology in developed countries; the performance, effectiveness and impact of regulation and individual regulatory policies in developed countries; the way new treatments diffuse; the nature of prevailing competition in medical technology markets and the impact of regulation; the use and impact of health technology assessment on health care; and the dynamics of innovation.
Second, to conduct research on prescribing, appropriateness and quality of care; in so doing, explore rational drug use, overuse, underuse and misuse of medications, their determinants and their potential impact on health care and outcomes.
Third, to conduct research on Access to medical technologies in developing, transition and emerging economies; In this area, we study and attempt to quantify the impact of health reforms and the uptake of health insurance in developing or emerging market, as well as assess the impact these are having on access to drug treatments. Also, study how economic and health policies affect access to medical technologies in developing countries.
Fourth, to conduct research on Disease management and the effectiveness of policies on medical technology, aiming to capture current information regarding the management and funding of chronic or life-threatening conditions, the extent to which national standards for the treatment of patients are defined, highlight advances in medical treatment and the determinants of their uptake in different health care systems as well as assess the performance of disease management policies or programmes across different health policy settings.
The Group administers, the Programme on Pharmaceutical Policy Issues (PPPI), the Programme on Medical Devices, conducts research under the auspices of and participates in the European Medicines Information Network (EMI-net) and the Network on Rare Diseases (BURQOL-RD), the Optimal Expenditure Network, and is a member of the European Health technology Institute for Socio-Economic Research (EHTI). It regularly works with the World Health Organization on projects related to pharmaceutical policy. MTRG also leads a consortium to advance and strengthen the methodological tools and practices relating to the application and implementation of health technology assessment (HTA) funded by European Commission under DG-Research 7th framework programme. It also coordinates The Patient Research Network, an initiative between academia, and individual health care stakeholders, including patients, practitioners and hospital managers to promote the diffusion of knowledge to stakeholder groups of health care issues and policies.